Merkesdal, Sonja <br/><br/>
Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.  [electronic resource] 

 -  The European journal of health economics : HEPAC : health economics in prevention and care  Feb 2010 
 - 95-104 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1618-7601 
<br/><br/><label>Standard No.: </label>10.1007/s10198-009-0205-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--economics<br/>Antirheumatic Agents--economics<br/>Arthritis, Rheumatoid--drug therapy<br/>Cost-Benefit Analysis<br/>Etanercept<br/>Female<br/>Germany<br/>Humans<br/>Immunoglobulin G--economics<br/>Immunosuppressive Agents--economics<br/>Male<br/>Markov Chains<br/>Middle Aged<br/>Models, Econometric<br/>Probability<br/>Quality-Adjusted Life Years<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Rituximab<br/>Surveys and Questionnaires<br/>Treatment Failure